Nexalin Technology Regains Nasdaq Compliance After Bid Price Cure

Nexalin Technology, Inc. has regained compliance with Nasdaq Listing Rule 5550(a)(2), which mandates a minimum closing bid price of $1.00 per share for issuers on The Nasdaq Capital Market. The company disclosed this development in a Current Report on Form 8-K filed with the Securities and Exchange Commission on October 1, 2026, citing formal notification received from The Nasdaq Stock Market LLC on September 30, 2026.

The cure follows a prior notification from the Hearings Panel of the Nasdaq dated September 25, 2026, which granted the company continued listing subject to specific conditions. According to the filing, the Panel required Nexalin to demonstrate compliance with the Minimum Bid Price Requirement on or before September 28, 2026. The company met this deadline, as confirmed by the subsequent notification from Nasdaq.

The listing exception remains conditional on a second requirement: Nexalin must demonstrate compliance with the minimum stockholders' equity requirement of $2,500,000 under Nasdaq Listing Rule 5550(b)(1) by January 4, 2027. The company stated its intention to take all necessary steps to satisfy this equity threshold within the specified timeframe. During this exception period, the company's common stock, traded under the symbol NXL on The Nasdaq Capital Market, will continue to be listed and traded, provided the company adheres to the terms of the Panel's notice.

The filing includes a cautionary note regarding future compliance. Nexalin indicated that there is no assurance it will be able to demonstrate compliance with the Stockholders' Equity Requirement by the January 4, 2027 deadline. Additionally, the company noted there is no guarantee it will maintain compliance with the Minimum Bid Price Requirement or other applicable continued listing rules. Failure to meet these conditions would subject the common stock to delisting from Nasdaq.

Nexalin Technology, Inc. is incorporated in Delaware and maintains its principal executive offices at 1776 Yorktown Street, Suite 550, Houston, Texas. The report was signed by Mark White, Chief Executive Officer.